Maurer, MarcusMarcusMaurerGiménez-Arnau, AnaAnaGiménez-ArnauBernstein, Jonathan AJonathan ABernsteinCHIA-YU CHUDanilycheva, InnaInnaDanilychevaHide, MichihiroMichihiroHideet al.,et al.2022-09-192022-09-1920220105-4538https://scholars.lib.ntu.edu.tw/handle/123456789/621159Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care therapy.enIgE; chronic spontaneous urticaria; ligelizumab; omalizumab; urticaria[SDGs]SDG3journal article10.1111/all.15175347732612-s2.0-85119502137WOS:000720841500001https://scholars.lib.ntu.edu.tw/handle/123456789/589801